Bioventix PLC (AIM:BVXP)
London · Delayed Price · Currency is GBP · Price in GBX 1,775.00
-25.00 (-1.39%)
Jan 22, 2026, 4:28 PM GMT
Bioventix Revenue
In the fiscal year ending June 30, 2025, Bioventix had annual revenue of 13.12M GBP, down -3.61%. Bioventix had revenue of 6.38M in the half year ending June 30, 2025, a decrease of -7.77%.
Revenue
13.12M
Revenue Growth
-3.61%
P/S Ratio
7.17
Revenue / Employee
1.09M
Employees
12
Market Cap
94.05M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 13.12M | -490.72K | -3.61% |
| Jun 30, 2024 | 13.61M | 790.36K | 6.17% |
| Jun 30, 2023 | 12.82M | 1.10M | 9.36% |
| Jun 30, 2022 | 11.72M | 788.68K | 7.22% |
| Jun 30, 2021 | 10.93M | 617.01K | 5.98% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| hVIVO | 54.47M |
| Arecor Therapeutics | 5.06M |
| Scancell Holdings | 4.71M |
| SkinBioTherapeutics | 4.64M |
| 4basebio | 1.78M |
| Ondine Biomedical | 1.18M |
| Avacta Group | 113.00K |
| ImmuPharma | -69.96K |
Bioventix News
- 3 months ago - AIM Market Roundup: Angle, Coyngar, Light Science Technologies - The Armchair Trader